Notice
Recent Posts
Recent Comments
Link
| 일 | 월 | 화 | 수 | 목 | 금 | 토 |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 |
Tags
- CAR-T in autoimmune
- VKTX
- danuglipron
- GPCR
- Novo Nordisk
- tern-601
- Semaglutide
- GLP-1 치료제
- CAR-T
- 비만치료제
- 제약바이오
- 경구용 glp-1
- Pegozafermin
- glp-1 비만
- Nash
- orforglipron
- Mash
- VK2735
- gsbr-1290
- 노보노디스크
- il-17 inhibitor
- Viking Therapeutics
- 자가면역질환 치료제
- 바이오스터디
- Efruxifermin
- tirzepatide
- structure therapeutics
- GLP-1치료제
- lilly
- GLP-1
Archives
- Today
- Total
제약바이오 츄롸이츄롸이
Tags
- 비만치료제
- GLP-1 치료제
- VK2735
- orforglipron
- Viking Therapeutics
- danuglipron
- VKTX
- CAR-T
- gsbr-1290
- glp-1 비만
- tern-601
- 경구용 glp-1
- Mash
- Novo Nordisk
- tirzepatide
- GLP-1
- 제약바이오
- Nash
- lilly
- Semaglutide
- 바이오스터디
- 노보노디스크
- GPCR
- il-17 inhibitor
- structure therapeutics
- 자가면역질환 치료제
- Pegozafermin
- Efruxifermin
- GLP-1치료제
- CAR-T in autoimmune
- Pfizer
- glp-1 비만치료제
- ct-996
- survodutide
- 2024 easl
- vk2809
- GLP-1/GIP
- MASH 치료제
- NASH 치료제
- 나스닥바이오
- ETNB
- MDGL
- AKRO
- 미국주식
- 세포치료제
- 릴리
- amlitelimab
- sonelokimab
- teprotumumab
- anti-myostatin
- cagrisema
- 2024 easd
- domvanalimab
- allogeneic cell therapy
- denifanstat
- nash/mash
- lotiglipron
- 2024 AACR
- Resmetirom
- 경구용 비만치료제
- 동종세포치료제
- 자가면역질환치료제
- NASH치료제
- CAR-NK
- SNAC
- BDTX
- TIGIT
- TED
- veritac-2
- er protac
- vepdegestrant
- arv-471
- cagrilintide
- redefine-1
- veligrotug
- vrdn-001
- vrdn
- scholar rock
- apitegromab
- maritide
- anti-cd19
- inebilizumab
- rocatinlimab
- amycretin
- 1l nsclc
- rilvegostomig
- belrestotug
- sana biotechnology
- 2024 eular
- 동종 세포치료제
- glp-1 비만 치료제
- glp-1 경구
- T-cell engager
- CGEM
- 2024 ASCO
- tovorafenib
- RAF 저해제
- RAF inhibitor
- CULLINAN ONCOLOGY
- Amivantamab
- EGFR Exon20ins
- RAPT therapeutics
- RYBELSUS
- Oncology Innovation Day
- MASH치료제
- C797S
- EGFR inhibitor
- CAR-T 치료제
- Allogeneic CAR-T
- Altimmune
- CRBU
- Black Diamond Therapeutics
- 스터디노트
- Ozempic
- RCUS
- MLTX
- 오젬픽
- thyroid eye disease
- FGF21
- 이중항체
- Gilead
- RAPT
- EGFR
- 면역항암제
- Tern
- Amgen
- 화이자
- 항암제
- venture oral
- viking therapeutics (nasdaq: vktx)
- povorcitinib
- hidradenitis suppurativa
- pemvidutide
- oral serd
- arvn
- surmount-2
- surmount-1
- redefine-2
- casdatifan
- arcus biosciences
- 비만 glp-1
- er+ bc
- veritac-3
- serd
- ox40/ox40l
- il-4/il-13 inhibitor
- adbry (tralokinumab)
- ebglyss (lebrikizumab)
- dupixent (dupilumab)
- anti-ox40lxtslp
- brivekimig
- tnfr1inhibitor oral
- balinatunfib
- anti-il13xtslp
- lunsekimig
- anti-ox40l
- galaxies-lung-301
- star-121
- anti-tigit
- iteos therapeutics
- 2025 asco gu
- 2025 asco gi
- dizal
- avbp
- sunvozertinib
- firmonertinib
- furmonertinib
- zipalertinib
- hidradenitis suppurative
- psoriatic arthritis
- immunovant (nasdaq: imvt)
- biohaven (nasdaq: bhvn)
- fcrn inhibitor
- thrive-1 thrive-2
- batoclimab
- viridian therapeutics (nasdaq: vrdn)
- tepezza
- thrive-2
- thrive-1
- pasi
- il-23 inhibitor
- plaque psoriasis
- risankizumab
- guselkumab
- bimekizumab
- ixekizumab
- secukinumab
- il-17
- glp-1 agonist gip antagonist
- glp-1 병용 비만
- gym329
- taldefgrobep alfa
- bvhn
- biohaven
- fcrn
- viridian therapeutics
- obesity week 2024
- sc제형 po제형
- nasdaq: vktx
- 비만 지방간염
- lean mass
- bimagrumab
- srk-439
- srk-423
- srk-015
- sma (spinal muscular atrophy)
- obesity week
- retatrutide
- 89bio
- akero therapeutics
- srrk
- 2024 ash
- 2024 acr
- tafasitamab
- blinatumomab
- gmg
- anti-ox40
- braf inhibitor
- braf v600x
- bidac degrader
- cft1946
- c4 therapeutics (nasdaq: cccc)
- amycretin oral
- lilly 릴리
- novo nordisk 노보노 디스크
- roche 로슈
- 2024 wclc
- ak112
- pd-1xvegfr
- akeso bio
- summit therapeutics
- ivonescimab
- fc effector function
- vibostolimab
- tiragolumab
- dostarlimab
- glp-1 경구용
- rgt-075
- cd47
- mhc ii knock-out
- mhc i knock-out
- hypoimmune
- terns pharma
- nasdaq: tern
- cd3 engager
- blincyto
- blintatumomab
- 자가세포치료제 vs. 동종세포치료제
- allogeneic car-t in 자가면역
- 2024 ada
- calcitonin
- amylin
- lortiglipron
- oral glp-1
- ft522
- f819
- 자가면역질환 세포치료제
- CLN-978
- Cullinan Therapeutics
- EGFR 저해제
- FDA 허가
- Day One Biopharma
- allogeneic CAR
- mRNA-4571
- BlakcDiamond Therapeutics
- Deciphera
- Kinnate
- Erasca
- DayOne Biopharma
- exarafenib
- belvarafenib
- naporafenib
- ARRIVENT
- ORIC Pharmaceuticals
- NKARTA
- 자가면역질환 CAR-T
- CPI 치료제
- KEYTRUDA
- Carmot Therapeutics
- GLP-1/GIP Dual Agonist
- REZDIFFRA
- Oral Formuatlion
- Oral Formulation
- Product Supply
- Research & Early Development
- Capital Market Day
- Capital Market Day 2024
- ADC 치료제
- 이중항체 치료제
- 2023 ESMO
- FGF21 Agonist
- SNDX
- Menin 저해제
- Menin Inhibitor
- THb agonist
- FGFR21
- GCG
- GIP
- EGFR저해제
- 자가면역치료제
- CAR세포치료제
- Allogeneic
- ESMO
- Novartis
- Caribou Biosciences
- BMEA
- sarcopenia
- 위고비
- 화농성 한선염
- 보로노이
- NKTX
- ORIC
- atopic dermatitis
- autoimmune
- CAR-T치료제
- Ustekinumab
- AstraZeneca
- Moderna
- lly
- Sanofi
- genentech
- AACR
- 키트루다
- Eli Lilly
- Kura
- 당뇨치료제
- muscle
- HS
- 자가세포치료제
- roche
- ipsc
- 지방간염
- t세포
- 자가면역질환
- sana
- NK세포
- NASDAQ
- ALT
- Dawn
- GSK
- ADC
- Papillon
- 근육
- Fate